Personalized Peptide Vaccine Shows Promise for Advanced Pancreatic Cancer | Research

The takeaway

A personalized neoantigen peptide vaccine (iNeo-Vac-P01) was safe and showed immune activation in advanced pancreatic cancer patients, with one patient achieving remarkable T-cell expansion and 21-month survival on vaccine therapy.

T-cell clone: 0% to ~100%
In the best responder, who survived 21 months on vaccine therapy for advanced pancreatic cancer

What the researchers found

Personalized neoantigen vaccine was safe in pancreatic cancer with low tumor mutation burden; one patient showed dramatic antigen-specific T-cell expansion from 0% to ~100% with 21-month vaccine-associated survival.

Why it matters

Pancreatic cancer has a 5-year survival rate under 10% and limited treatment options. This is among the first studies showing personalized neoantigen vaccines can work even in cancers with low mutation burden.

The numbers in context

7 patients; up to 20 peptides each; TMB <10; OS 24.1 mo; vaccine OS 8.3 mo; PFS 3.1 mo; P01: 21 mo, TCR 0→~100%

How the study worked

Retrospective study of 7 advanced pancreatic cancer patients. Up to 20 neoantigen peptides per patient identified by iNeo-Suite pipeline. Multiple vaccine doses administered. Immune monitoring via ELISpot and flow cytometry pre/post-vaccination.

Who was studied

7 advanced pancreatic cancer patients refractory to standard treatment, low TMB

What this study cannot tell us

Very small sample (n=7). Retrospective design. No control group. Heterogeneous patient population. Cannot definitively attribute survival to vaccine therapy.

How to read the evidence

Very small retrospective study (n=7) providing proof-of-concept. Individual case results are dramatic but require larger trial confirmation.

When this study was published

Published in 2021, representing early clinical experience with personalized neoantigen vaccines in pancreatic cancer.

The bigger picture

Pancreatic cancer has been resistant to immunotherapy approaches that work in other cancers. Demonstrating that personalized peptide vaccines can activate meaningful immune responses — even in a cancer with few mutations — opens a new avenue for treating one of the deadliest cancers.

Questions still open

Would a randomized trial confirm survival benefit?
Can the T-cell expansion seen in the best responder be replicated in more patients?
Would combining neoantigen vaccines with checkpoint inhibitors improve outcomes?

Common questions

How does a personalized cancer vaccine work?

Scientists sequence the patient's tumor DNA to find unique mutations. They then create custom peptides matching these mutations and vaccinate the patient, training their immune system's T cells to recognize and attack cells carrying those specific mutations.

Why is this important for pancreatic cancer?

Pancreatic cancer is one of the deadliest cancers with few effective treatments. It typically has few mutations, which makes it a challenging target for immunotherapy. This study shows that personalized vaccines can still activate strong immune responses even in cancers with low mutation burden.

Read the original research

A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.

Frontiers in immunology, 12, 691605

View on PubMed ↗Publisher’s paper ↗

Citation

Chen, Zheling; Zhang, Shanshan; Han, Ning; Jiang, Jiahong; Xu, Yunyun; Ma, Dongying; Lu, Lantian; Guo, Xiaojie; Qiu, Min; Huang, Qinxue; Wang, Huimin; Mo, Fan; Chen, Shuqing; Yang, Liu. (2021). A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.. Frontiers in immunology, 12, 691605. https://doi.org/10.3389/fimmu.2021.691605